{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.71075","value":"14.1440"},{"groupId":"OG001","spread":"8.43282","value":"25.6360"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Creatinine: Change at Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.4200","value":"-1.710"},{"groupId":"OG001","spread":"6.1655","value":"-3.420"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Bilirubin: Change at Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2092","value":"0.855"},{"comment":"NA indicates that standard deviation was not estimated for single participant.","groupId":"OG001","spread":"NA","value":"-3.420"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Direct Bilirubin: Change at Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2092","value":"0.855"},{"comment":"NA indicates that standard deviation was not estimated for single participant.","groupId":"OG001","spread":"NA","value":"-6.840"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Indirect Bilirubin: Change at Day 100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Clinical serum chemistry tests included renal function parameters i.e. creatinine and bilirubin. Change from baseline in clinical serum chemistry tests i.e. renal function parameters at Day 100 were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received single dose of tinostamustine 180 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG000","title":"Tinostamustine 180 mg/m^2"},{"description":"Participants received single dose of tinostamustine 220 mg/m\\^2 IV injection on Day -1 followed by ASCT on Day 1.","id":"OG001","title":"Tinostamustine 220 mg/m^2"}],"paramType":"MEAN","populationDescription":"Safety population included all participants who received tinostamustine. The study was early terminated on 17 April 2019, due to safety signals during Phase 1, participants were not enrolled in Phase 2. Here, number analyzed refers to the number of participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -1), Day 100","title":"Phase 1 and 2: Change From Baseline in Clinical Serum Chemistry Tests: Renal Function Parameters","type":"SECONDARY","unitOfMeasure":"millimoles per liter (mmol/L)"}